Gleolan Approval History
- FDA approved: Yes (First approved June 6th, 2017)
- Brand name: Gleolan
- Generic name: aminolevulinic acid hydrochloride
- Dosage form: Oral Solution
- Company: NX Development Corp.
- Treatment for: Optical Imaging During Glioma Surgery
Gleolan (aminolevulinic acid hydrochloride) is an optical imaging agent indicated for use in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Development History and FDA Approval Process for Gleolan
|Jun 6, 2017||FDA Approves Gleolan (aminolevulinic acid hydrochloride) as an Optical Imaging Agent in Patients with Gliomas|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.